Randomized, double-blind, placebo-controlled phase III trial to evaluate the effectiveness of a phosphodiesterase 5 inhibitor, tadalafil, in prevention of erectile dysfunction in patients treated with radiotherapy for prostate cancer

eagle-i ID

Resource Type

Properties

1. ClinicalTrials.gov url

   http://www.clinicaltrials.gov/ct2/show/NCT00931528?term=RTOG-0831&rank=1

2. Intervention

   Tadalafil

3. Resource Description

   RATIONALE: Tadalafil may help prevent erectile dysfunction in patients with prostate cancer that have been treated with radiation therapy. It is not yet known whether tadalafil is more effective than a placebo in preventing erectile dysfunction. PURPOSE: This randomized phase III trial is studying tadalafil to see how well it works compared with a placebo in preventing erectile dysfunction in patients with prostate cancer treated with radiation therapy.

4. Contact

   Berenberg, Jeffrey

5. PI

   Berenberg, Jeffrey

6. Topic

   prostate cancer

7. Study Population

   Males age 18 and older with diagnosis of adenocarcinoma of the prostate within the past 6 months.

8. Website(s)

   http://www.cancer.gov/clinicaltrials/search/view?cdrid=647146&version=healthprofessional

9. Funded by

   Radiation Therapy Oncology Group

10. Phase

    Phase 3 clinical trial

11. Performed by

    Clinical Protocol & Data Management Shared Resource